Literature DB >> 17628829

Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance.

José M del Casar1, María D Corte, Ana Alvarez, Isabel García, Miguel Bongera, Luis O González, José L García-Muñiz, María T Allende, Aurora Astudillo, Francisco J Vizoso.   

Abstract

BACKGROUND: Lymphatic and/or blood vessel tumoral invasion (LBVI) is a common histopathologic finding of gastric carcinomas, which could make it an additional cost efficient marker and help in the detection of patients at risk for recurrence.
MATERIALS AND METHODS: The subjects of this study were 144 patients with primary gastric adenocarcinoma, who consecutively underwent surgery. LBVI was evaluated by H&E staining and complementary with immunohistochemical staining with anti-CD34. Intratumoral levels of EGFR were analyzed with a radioligand technique, whereas c-erbB-2 and tPA were determined by ELISA methods; pS2, cathepsin D and hyaluronic acid by immunoradiometric assays; and VEGFR-1 and -2 by immunohistochemical assays. The mean follow-up period for these patients was 33.1 months.
RESULTS: LBVI was present in 46 patients (31.9%). The presence of LBVI correlated significantly with tumor stage, lymph node involvement, surgical resectability, histological type and histological grade, being present in a higher percentage among II-IV tumor stage (P = 0.0001), poorly differentiated (P = 0.01), diffuse type (P = 0.009), R1-R2 (P = 0.002) and lymph node-positive (P = 0.005) tumors. In addition, statistical analysis demonstrated that LBVI was significantly associated with a poorer overall patients' survival in the univariate analysis (P = 0.0001) as well as in the multivariate analysis (P = 0.009). However, our results failed to show any significant relationship between LBVI and any of the intratumoral biological parameters studied.
CONCLUSION: LBVI provides additional useful information that could be applied to identify gastric cancer patients at risk for recurrence, who might be candidates for further adjuvant therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17628829     DOI: 10.1007/s00432-007-0264-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  47 in total

Review 1.  The use of molecular biology in diagnosis and prognosis of gastric cancer.

Authors:  K F Becker; G Keller; H Hoefler
Journal:  Surg Oncol       Date:  2000-07       Impact factor: 3.279

2.  Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction.

Authors:  Burkhard H A von Rahden; Hubert J Stein; Marcus Feith; Karen Becker; J Rüdiger Siewert
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

3.  Carcinomatous lymphatic invasion in early gastric cancer invading into the submucosa.

Authors:  S Ishigami; S Natsugoe; S Hokita; M Tokushige; T Saihara; T Watanabe; K Aridome; H Iwashige; T Aikou
Journal:  Ann Surg Oncol       Date:  1999 Apr-May       Impact factor: 5.344

4.  Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer.

Authors:  Jin-Pok Kim; Joo-Ho Lee; Soo-Jin Kim; Hang-Jong Yu; Han-Kwang Yang
Journal:  Gastric Cancer       Date:  1998-03       Impact factor: 7.370

5.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation.

Authors:  A J Leu; D A Berk; A Lymboussaki; K Alitalo; R K Jain
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

6.  Lymphatic metastasis in the absence of functional intratumor lymphatics.

Authors:  Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2002-04-25       Impact factor: 47.728

7.  Early gastric cancer: follow-up after gastrectomy in 159 patients.

Authors:  S Guadagni; P I Reed; B J Johnston; G De Bernardinis; M Catarci; M Valenti; F di Orio; M Carboni
Journal:  Br J Surg       Date:  1993-03       Impact factor: 6.939

8.  Tissue-type plasminogen activator (tPA) content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance.

Authors:  P Raigoso; A Junco; A Andicoechea; A Gonzalez; J L García-Muñiz; M T Allende; M García-Morán; F Vizoso
Journal:  Int J Biol Markers       Date:  2000 Jan-Mar       Impact factor: 3.248

9.  Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration.

Authors:  L P Setälä; V M Kosma; S Marin; P K Lipponen; M J Eskelinen; K J Syrjänen; E M Alhava
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

10.  Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer.

Authors:  T Arigami; S Natsugoe; Y Uenosono; H Arima; Y Mataki; K Ehi; S Yanagida; S Ishigami; S Hokita; T Aikou
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640

View more
  17 in total

1.  Effect of lymphadenectomy extent on advanced gastric cancer located in the cardia and fundus.

Authors:  Chang-Ming Huang; Bi-Juan Lin; Hui-Shan Lu; Xiang-Fu Zhang; Ping Li; Jian-Wei Xie
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

2.  Effect of Helicobacter pylori infection on outcomes in resected gastric and gastroesophageal junction cancer.

Authors:  Jennifer M Kolb; Umut Ozbek; Noam Harpaz; Randall F Holcombe; Celina Ang
Journal:  J Gastrointest Oncol       Date:  2017-06

3.  Pathological evaluation of gastrointestinal endoscopic submucosal dissection materials based on Japanese guidelines.

Authors:  Koji Nagata; Michio Shimizu
Journal:  World J Gastrointest Endosc       Date:  2012-11-16

4.  Impact of lymphatic and/or blood vessel invasion in stage II gastric cancer.

Authors:  Chun-Yan Du; Jing-Gui Chen; Ye Zhou; Guang-Fa Zhao; Hong Fu; Xue-Ke Zhou; Ying-Qiang Shi
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

5.  Lymphatic vascular invasion is an independent correlated factor for lymph node metastasis and the prognosis of resectable T2 gastric cancer patients.

Authors:  Zhaode Bu; Zhixue Zheng; Ziyu Li; Lianhai Zhang; Aiwen Wu; Xiaojiang Wu; Yu Sun; Jiafu Ji
Journal:  Tumour Biol       Date:  2013-01-06

6.  Vascular invasion as an independent predictor of poor prognosis in nonmetastatic gastric cancer after curative resection.

Authors:  Peng Li; Yi-Hong Ling; Chong-Mei Zhu; Wan-Ming Hu; Xin-Ke Zhang; Rong-Zhen Luo; Jie-Hua He; Jing-Ping Yun; Yuan-Fang Li; Mu-Yan Cai
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

7.  Microanalysis of stomach cancer glycosaminoglycans.

Authors:  Amanda Weyers; Bo Yang; Jong-Hwan Park; Yong-Seok Kim; Sun-Moon Kim; Sang-Eok Lee; Fuming Zhang; Kyung Bok Lee; Robert J Linhardt
Journal:  Glycoconj J       Date:  2013-04-21       Impact factor: 2.916

8.  The prognostic significance of lymphovascular invasion in patients with resectable gastric cancer: a large retrospective study from Southern China.

Authors:  Peng Li; Hao-Qiang He; Chong-Mei Zhu; Yi-Hong Ling; Wan-Ming Hu; Xin-Ke Zhang; Rong-Zhen Luo; Jing-Ping Yun; Dan Xie; Yuan-Fang Li; Mu-Yan Cai
Journal:  BMC Cancer       Date:  2015-05-07       Impact factor: 4.430

9.  N,N'-dinitrosopiperazine-mediated AGR2 is involved in metastasis of nasopharyngeal carcinoma.

Authors:  Yuejin Li; Jinping Lu; Zhengke Peng; Gongjun Tan; Na Liu; Damao Huang; Zhenlin Zhang; Chaojun Duan; Xiaowei Tang; Faqing Tang
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

10.  Proteomic analysis on N, N'-dinitrosopiperazine-mediated metastasis of nasopharyngeal carcinoma 6-10B cells.

Authors:  Yuejin Li; Na Liu; Damao Huang; Zhenlin Zhang; Zhengke Peng; Chaojun Duan; Xiaowei Tang; Gongjun Tan; Guangrong Yan; Wenhua Mei; Faqing Tang
Journal:  BMC Biochem       Date:  2012-11-19       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.